87153-04-6 Usage
Uses
Used in Pharmaceutical Industry:
3,4-DIHYDRO-6-[4-[1-(TRANS-4-HYDROXYCYCLOHEXYL)-1H-TETRAZOL-5-YL]BUTOXY]-2(1H)-QUINOLINONE is used as a pharmaceutical compound for its potential therapeutic effects. Its unique structure allows it to interact with biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
3,4-DIHYDRO-6-[4-[1-(TRANS-4-HYDROXYCYCLOHEXYL)-1H-TETRAZOL-5-YL]BUTOXY]-2(1H)-QUINOLINONE is also used in chemical research for its unique properties and potential applications. Researchers can study its chemical behavior and interactions with other molecules to gain insights into its potential uses and develop new applications.
Used as a Labelled Metabolite:
3,4-DIHYDRO-6-[4-[1-(TRANS-4-HYDROXYCYCLOHEXYL)-1H-TETRAZOL-5-YL]BUTOXY]-2(1H)-QUINOLINONE can be used as a labelled metabolite in various analytical techniques. Its unique structure and properties make it suitable for tracking and analyzing metabolic pathways, which can be useful in both research and clinical settings.
Chemical Properties:
3,4-DIHYDRO-6-[4-[1-(TRANS-4-HYDROXYCYCLOHEXYL)-1H-TETRAZOL-5-YL]BUTOXY]-2(1H)-QUINOLINONE is a white to off-white solid, indicating its stability and potential for use in various applications. Its solid-state properties can be further studied to understand its behavior in different environments and its interactions with other compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 87153-04-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,1,5 and 3 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 87153-04:
(7*8)+(6*7)+(5*1)+(4*5)+(3*3)+(2*0)+(1*4)=136
136 % 10 = 6
So 87153-04-6 is a valid CAS Registry Number.
InChI:InChI=1/C20H27N5O3/c26-16-7-5-15(6-8-16)25-19(22-23-24-25)3-1-2-12-28-17-9-10-18-14(13-17)4-11-20(27)21-18/h9-10,13,15-16,26H,1-8,11-12H2,(H,21,27)/t15?,16-
87153-04-6Relevant academic research and scientific papers
The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man
Akiyama,Kudo,Shimizu
, p. 1133 - 1140 (2007/10/02)
The metabolism of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxyl]-3,4-dihydro-2(1H)-quinolinon e, OPC-13013) was studied after the oral administration of cilostazol or 14C-cilostazol in rats, dogs and man. Metabolites of cilostazol identified in the rat, dog and human plasma and urine were monohydroxycilostazol (OPC-13213, OPC-13217, OPC-13366, OPC-13371, OPC-13215 and OPC-13326), monohydroxydehydrocilostazol (OPC-13269 and OPC-13388), 3,3-dihydro-6-hydroxy-2(1H)-quinolinone (6-HQ), their conjugates and dehydrocilostazol (OPC-13015). Major metabolites detected in the rat plasma were OPC-13015, OPC-13217 and OPC-13213, and the plasma concentration of OPC-13015 was 53 to 79% of that of cilostazol. In the dog plasma, major metabolites detected were OPC-13213, OPC-13366 and OPC-13015, and the AUC of OPC-13213 was 79.7% of that of cilostazol. In the human plasma, major metabolites detected were OPC-13015 and OPC-13213, and their AUC were 11.7 and 9.1% of that of cilostazol, respectively. Monohydroxycilostazol and monohydroxydehydrocilostazol were detected at 8.5% of dose in the rat urine and 8.7% in the dog urine, and OPC-13213 showed the highest concentration of these. The conjugates of these and 6-HQ were detected at 0.4 and 24.5%, respectively, in the rat urine and 2.4 and 3.7%, respectively, in the dog urine. These conjugates were mainly sulfate in rats and glucuronide in dogs. In the human urine, OPC-13213 showed the highest concentration, and the conjugates were mainly glucuronide. No cilostazol or OPC-13015 was detected in the rat, dog or human urine at all. Metabolites detected in the rat and dog feces were mainly monohydroxycilostazol, monohydroxydehydrocilostazol and 6-HQ, and cilostazol was detected at 12.0 and 49.3% of dose, respectively.
